Table 1 Baseline characteristics in the two groups
Dexmedetomidine + remifentanil (N = 121) | Midazolam + fentanyl (N = 119) | p value | |
|---|---|---|---|
Age, years | 62.0 ± 10.6 | 60.4 ± 11.0 | 0.265 |
Male, n (%) | 78 (64.5%) | 84 (70.6%) | 0.311 |
Height, cm | 164.6 ± 9.4 | 164.6 ± 8.3 | 0.943 |
Weight, kg | 67.9 ± 11.2 | 68.8 ± 12.6 | 0.580 |
BMI, kg/m2 | 25.0 ± 3.0 | 25.4 ± 3.7 | 0.321 |
BSA, m2 | 1.76 ± 0.18 | 1.77 ± 0.19 | 0.626 |
SR at the beginning of the procedure | 74 (61.2%) | 73 (61.3%) | 0.973 |
SBP, mmHg | 143 ± 21 | 137 ± 23 | 0.015 |
DBP, mmHg | 86 ± 13 | 81 ± 12 | 0.004 |
Heart rate, beats per min | 70 ± 21 | 76 ± 19 | 0.017 |
ASA class ≤ 2 | 76 (62.8%) | 73 (61.3%) | 0.815 |
Hypertension, n (%) | 67 (55.4%) | 68 (57.1%) | 0.782 |
Diabetes mellitus, n (%) | 22 (18.2%) | 23 (19.3%) | 0.820 |
Stroke, n (%) | 11 (9.1%) | 14 (11.8%) | 0.498 |
Heart failure, n (%) | 15 (12.4%) | 6 (5.0%) | 0.066 |
Coronary artery, n (%) disease | 7 (5.8%) | 8 (6.7%) | 0.764 |
Left ventricular ejection fraction, % | 59.1 ± 6.8 | 60.4 ± 6.3 | 0.127 |
Procedure time, min | 215 ± 55 | 215 ± 50 | 0.995 |
Dosage (midazolam or dexmedetomidine), μg/kg/h | Dexmedetomidine 0.86 ± 0.19 | Midazolam 95.6 ± 21.1 | |
Dosage (fentanyl or remifentanil), μg/kg/h | Remifentanil 3.40 ± 0.82 | Fentanyl 1.74 ± 0.40 |